4.5 Article

Association between Levels of C-Reactive Protein and Leukocytes and Cancer: Three Repeated Measurements in the Swedish AMORIS Study

期刊

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
卷 20, 期 3, 页码 428-437

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-10-1190

关键词

-

资金

  1. Gunnar and Ingmar Jungner Foundation for Laboratory Medicine (Stockholm)
  2. Cancer Research UK

向作者/读者索取更多资源

Objective: To study levels of C-reactive protein (CRP) and leukocytes, as inflammatory markers, in the context of cancer risk. Methods: From the Apolipoprotein MOrtality RISk (AMORIS) study, we selected 102,749 persons with one measurement and 9,273 persons with three repeated measurements of CRP and leukocytes. Multivariate Cox proportional hazards regression was applied to categories of CRP (< 10, 10-15, 15-25, 25-50, > 50 g/L) and quartiles of leukocytes. An inflammation-based predictive score (IPS) indicated whether someone had CRP levels of more than 10 mg/L combined with leukocytes of more than 10 x 10(9) /L. Reverse causality was assessed by excluding those with less than 3, 5, or 7 years of follow-up. To analyze repeated measurements of CRP and leukocytes, the repeated IPS (IPS(r)) was calculated by adding the IPS of each measurement. Results: In the cohort with one measurement, there was a positive trend between CRP and risk of developing cancer, with the lowest category being the 0.99 (0.92-1.06), 1.28 (1.11-1.47), 1.27 (1.09-1.49), and 1.22 (1.01-1.48) for the second to fifth categories, respectively. This association disappeared when excluding those with follow-up of less than 3, 5, or 7 years. The association between leukocytes and cancer was slightly stronger. In the cohort with repeated measurements, the IPSr was strongly associated with cancer risk: 1.87 (1.33-2.63), 1.51 (0.56-4.06), and 4.46 (1.43-13.87) for IPSr 1, 2, and 3 compared with IPS(r) = 0. The association remained after excluding those with follow-up of less than 1 year. Conclusions and Impact: Our large, prospective cohort study adds evidence for a link between inflammatory markers and cancer risk by using repeated measurements and ascertaining reverse causality. Cancer Epidemiol Biomarkers Prev; 20(3); 428-37. (C)2011 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据